` CIPLA (Cipla Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

CIPLA
vs
BSE Sensex 30

Over the past 12 months, CIPLA has underperformed BSE Sensex 30, delivering a return of -4% compared to the BSE Sensex 30's 5% growth.

Stocks Performance
CIPLA vs BSE Sensex 30

Loading

Performance Gap
CIPLA vs BSE Sensex 30

Loading
CIPLA
BSE Sensex 30
Difference

Performance By Year
CIPLA vs BSE Sensex 30

Loading
CIPLA
BSE Sensex 30
Add Stock

Competitors Performance
Cipla Ltd vs Peers

BSE Sensex 30
CIPLA
LLY
JNJ
NOVO B
ROG
Add Stock

Cipla Ltd
Glance View

Economic Moat
Narrow
Market Cap
1.2T INR
Industry
Pharmaceuticals

In the bustling heart of India's pharmaceutical landscape, Cipla Ltd. stands as a venerable name, tracing its roots back to 1935. Founded by Khwaja Abdul Hamied, Cipla embarked on a journey fueled by the vision of making healthcare accessible and affordable to the masses. Over decades, the company has morphed into a global pharmaceutical powerhouse, seamlessly integrating science and compassion. Cipla primarily operates through the production and sale of active pharmaceutical ingredients (APIs) and a wide array of generic medicines, catering to various therapeutic segments such as respiratory, anti-retroviral, urology, cardiology, and oncology. The company’s manufacturing prowess is underpinned by its state-of-the-art facilities, strategically located to serve markets across the globe, ensuring its competitive edge in quality and cost-efficiency. Cipla's revenue streams elegantly dance around its core philosophy—offering affordable medication without compromising quality. The company capitalizes on its robust R&D capabilities to develop and market generics that serve as cost-effective alternatives to patented medicines. Its business model thrives on the volume-driven sale of these generics, both in domestic and international markets. Additionally, Cipla reinforces its revenue through strategic partnerships and collaborations across the pharmaceutical value chain, and by out-licensing its products in various regions. By continually expanding its pipeline to include biosimilars and new drug delivery systems, Cipla not only strengthens its foothold in existing markets but also pioneers growth into new pharmaceutical frontiers.

CIPLA Intrinsic Value
1 179.42 INR
Overvaluation 18%
Intrinsic Value
Price
Back to Top